| abstract |
The inventions include, for example, pharmaceutical compositions, formulations and dosage forms having a pharmaceutically acceptable copper antagonist compound(s) or a pharmaceutically acceptable salt or prodrug thereof, including copper (II) antagonists, and an insulin; articles, kits and delivery devices containing such compositions, formulations and dosage forms; and methods of use for treatment of subjects, including humans, who have or are at risk for various diseases, disorders, and conditions, including, for example, glucose metabolism disorders, and diseases, disorders or conditions characterized in whole or in part by hypercupremia and/or hyperglycemia. |